Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Refractive sales rose 55.5% to $120.5 million. Pro forma refractive sales rose 3.1%.

This excerpt taken from the EYE 8-K filed May 1, 2008.

Refractive sales rose 55.5% to $120.5 million. Pro forma refractive sales rose 3.1%.

 

  •  

Procedures, implants and related sales rose 46% to $85.4 million, or 3.9% on a pro forma basis as softness in the U.S. excimer and refractive IOL market was offset by increased global penetration of the company’s IntraLase technology, and international growth of all its refractive procedures and implants.

 

  •  

AMO’s U.S. excimer procedure volumes declined approximately 10% in the first quarter and were virtually unchanged for the trailing 12 months ended March 28, 2008. For the trailing 12 months ended March 28, 2008, the company’s U.S. custom mix was 66%; the first-quarter custom mix was 69%, compared to 64% in the year-ago quarter.

 

  •  

AMO’s U.S. femtosecond procedure volumes rose approximately 16% in the first quarter and 29.8% for the trailing 12 months ended March 28, 2008, on a pro forma basis.

 

  •  

AMO’s international procedure, implant and related sales were $27.8 million, up 200%, or 48.5% on a pro forma basis.

 

 

•

  

System sales rose 158.1%, or 19.4% on a pro forma basis, to $26.8 million. Unit placements of the VISX® Star S4IR® excimer laser rose 10.0%. IntraLase® FS laser placements rose 35.4% on a pro forma basis. The increases reflect continued demand for the company’s dual platform worldwide.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki